Cost Effectiveness, Quality-Adjusted Life-Years and Supportive Care: Recombinant Human Erythropoietin as a Treatment of Cancer-Associated Anaemia

Author： Cremieux P-Y.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.16, Iss.5, 1999-11, pp. : 459-472

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recombinant Human Erythropoietin for the Treatment of Renal Anaemia in Children: No Justification for Bodyweight-Adjusted Dosage

By Port R.E.  

Clinical Pharmacokinetics, Vol. 43, Iss. 1, 2004-01 ,pp. : 57-70

Adis International

Access to resources Recommend Favorite

The techniques used as a basis from which to calculate quality-adjusted life-years (QALYs) are flawed

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 370, 2002-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Recombinant Erythropoietin for Chemotherapy-Related Anaemia: Economic Value and Health-Related Quality-of-Life Assessment Using Direct Utility Elicitation and Discrete Choice Experiment Methods

By Ossa Diego F.  

PharmacoEconomics, Vol. 25, Iss. 3, 2007-01 ,pp. : 223-237

Adis International

Access to resources Recommend Favorite

Recombinant Erythropoietin for Anaemia of Prematurity—When Should Treatment Start?

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 37, Iss. 3, 2007-09 ,pp. : 217-219

John Wiley & Sons Inc

Access to resources Recommend Favorite

A report commissioned by the Dutch government says that treatments which cost > €80 000 for every extra quality-adjusted life year should not be covered

By  

Inpharma, Vol. 1, Iss. 1550, 2006-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite